SCHEDULE: Vanguard Discloses 5.53% Stake in Protagonist Therapeutics

Vanguard Portfolio Management has reported beneficial ownership of 5.53% of Protagonist Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Portfolio Management, along with its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, has disclosed a beneficial ownership of 3,533,015 shares of Protagonist Therapeutics Inc. common stock.
• This holding represents 5.53% of the total class of securities.
• The filing indicates that Vanguard Portfolio Management has sole dispositive power over these shares and sole voting power over 51,804 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of institutional ownership and does not provide new operational or financial performance information about Protagonist Therapeutics.

Positives

• Significant institutional ownership by a major asset manager like Vanguard can provide stability and confidence to the market.
• The disclosure confirms Vanguard's investment in Protagonist Therapeutics, potentially signaling a positive view on the company's prospects.

Risks

• While not explicitly stated as a risk in this filing, a large stake held by an institutional investor could lead to significant selling pressure if Vanguard decides to divest its position.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Protagonist Therapeutics Inc.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major asset manager like Vanguard indicates significant institutional interest in a biotechnology company like Protagonist Therapeutics, which is typical for companies in the clinical development phase.

Stakeholder Impact

• Shareholders: The presence of a significant institutional investor like Vanguard can be seen as a positive signal, potentially increasing investor confidence. However, future decisions by Vanguard regarding its stake could impact share price.
• Company Management: The filing confirms Vanguard's investment, which may be viewed favorably by Protagonist Therapeutics' management.
• Other Investors: This disclosure provides transparency regarding significant ownership, allowing other investors to assess the company's shareholder base.

Next Steps

• Vanguard will continue to hold or manage its stake in Protagonist Therapeutics according to its investment strategies.
• Protagonist Therapeutics Inc. will continue its business operations and disclosures as required.

Key Dates

Keywords

Protagonist Therapeutics, Vanguard, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing